Washington PostPeril resides in the promise of gene editingWashington PostThis is the weekly roundup of The WorldPost, of which Nathan Gardels is the editor in chief. Of all the prodigious advances in technology taking place today, none is more profoun… Continue reading
Genetic Engineering & Biotechnology NewsNew insights could lead to lasting improvement of stem cell therapy in horsesScience Daily"While the human endometrium is known to harbour stem cells, these had previously not been identified in equine endom… Continue reading
Medical News TodayHemophilia cure? Gene therapy trial shows dramatic resultsMedical News TodayA report on the trial, which is published in the New England Journal of Medicine, describes how, more than a year after receiving a single dose of gene therap… Continue reading
Cancer Therapy AdvisorPriming Lung Cancer To Respond to Immunotherapy: Findings and Current ResearchCancer Therapy AdvisorCombining 5-azacytidine (a demethylating drug) with a histone deacetylase (HDAC) inhibitor may prime non–small cell lung cancers (… Continue reading
OncLiveImmunotherapy Resistance Remains a PuzzleOncLiveAntoni Ribas, MD, PhD, a leading authority on immunotherapy and a Giants of Cancer Care® awardwinner, and colleagues have defined 3 types of resistance to immunotherapy that have been manifested in… Continue reading
Prime Time for CAR T CellsOncLiveChimeric antigen receptor (CAR) T cells have hit prime time, with the 2 recent FDA approvals for this class of cell-based therapy. Undoubtedly this option will be a game changer for patients with B-cell malignancies who… Continue reading
Business Wire |
Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn’s disease
BioWorld Online LONDON – Eight years on from securing the first EMA approval for an autologous cell therapy, Tigenix NV has done it again, getting the nod for the first allogeneic adipose-derived stem cell therapy, Alofisel (Cx601, darvadstrocel), in the treatment of … Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex …Nasdaq |
Business Wire |
Tigenix gets EMA nod for off-the-shelf stem cell therapy in Crohn’s disease
BioWorld Online LONDON – Eight years on from securing the first EMA approval for an autologous cell therapy, Tigenix NV has done it again, getting the nod for the first allogeneic adipose-derived stem cell therapy, Alofisel (Cx601, darvadstrocel), in the treatment of … Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex …Nasdaq |